Literature DB >> 30887440

The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder.

Evan S Cole1, Ellen DiDomenico2, Gerald Cochran3, Adam J Gordon3, Walid F Gellad4,5, Janice Pringle6, Jack Warwick6, Chung-Chou H Chang5, Joo Yeon Kim4, Julie Kmiec7, David Kelley8, Julie M Donohue4.   

Abstract

BACKGROUND: The opioid epidemic has disproportionately affected rural areas, where a limited number of health care providers offer medication-assisted treatment (MAT), the mainstay of treatment for opioid use disorder (OUD). Rural residents with OUD may face multiple barriers to engagement in MAT including long travel distances.
OBJECTIVE: To examine the degree to which rural residents with OUD are engaged with primary care providers (PCPs), describe the role of rural PCPs in MAT delivery, and estimate the association between enrollee distance to MAT prescribers and MAT utilization.
DESIGN: Retrospective cohort study. PARTICIPANTS: Medicaid-enrolled adults diagnosed with OUD in 23 rural Pennsylvania counties. MAIN MEASURES: Primary care utilization, MAT utilization, distance to nearest possible MAT prescriber, mean distance traveled to actual MAT prescribers, and continuity of pharmacotherapy. KEY
RESULTS: Of the 7930 Medicaid enrollees with a diagnosis of OUD, a minority (18.6%) received their diagnosis during a PCP visit even though enrollees with OUD had 4.1 visits to PCPs per person-year in 2015. Among enrollees with an OUD diagnosis recorded during a PCP visit, about half (751, 50.8%) received MAT, most of whom (508, 67.6%) received MAT from a PCP. Enrollees with OUD with at least one PCP visit were more likely than those without a PCP visit to receive MAT (32.7% vs. 25%; p < 0.001), and filled more buprenorphine and naltrexone prescriptions (mean = 11.1 vs. 9.3; p < 0.001). The median of the distances traveled to actual MAT prescribers was 48.8 miles, compared to a median of 4.2 miles to the nearest available MAT prescriber. Enrollees traveling a mean distance greater than 45 miles to MAT prescribers were less likely to receive continuity of pharmacotherapy (OR = 0.71, 95% CI = 0.56-0.91, p = 0.007).
CONCLUSIONS: PCP utilization among rural Medicaid enrollees diagnosed with OUD is high, presenting a potential intervention point to treat OUD, particularly if the enrollee's PCP is located nearer than their MAT prescriber.

Entities:  

Keywords:  medication-assisted treatment; opioid use disorder; primary care; rural

Year:  2019        PMID: 30887440      PMCID: PMC6544707          DOI: 10.1007/s11606-019-04943-6

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  13 in total

1.  Distance is relative: unpacking a principal barrier in rural healthcare.

Authors:  Colin Buzza; Sarah S Ono; Carolyn Turvey; Stacy Wittrock; Matt Noble; Gautam Reddy; Peter J Kaboli; Heather Schacht Reisinger
Journal:  J Gen Intern Med       Date:  2011-11       Impact factor: 5.128

2.  Barriers to primary care physicians prescribing buprenorphine.

Authors:  Eliza Hutchinson; Mary Catlin; C Holly A Andrilla; Laura-Mae Baldwin; Roger A Rosenblatt
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

3.  Geographic and specialty distribution of US physicians trained to treat opioid use disorder.

Authors:  Roger A Rosenblatt; C Holly A Andrilla; Mary Catlin; Eric H Larson
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

4.  Growth In Buprenorphine Waivers For Physicians Increased Potential Access To Opioid Agonist Treatment, 2002-11.

Authors:  Andrew W Dick; Rosalie L Pacula; Adam J Gordon; Mark Sorbero; Rachel M Burns; Douglas Leslie; Bradley D Stein
Journal:  Health Aff (Millwood)       Date:  2015-06       Impact factor: 6.301

5.  Performance Measures of Diagnostic Codes for Detecting Opioid Overdose in the Emergency Department.

Authors:  Christopher Rowe; Eric Vittinghoff; Glenn-Milo Santos; Emily Behar; Caitlin Turner; Phillip O Coffin
Journal:  Acad Emerg Med       Date:  2017-03-17       Impact factor: 3.451

Review 6.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

7.  Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.

Authors:  Wendy Kissin; Caroline McLeod; Joseph Sonnefeld; Arlene Stanton
Journal:  J Addict Dis       Date:  2006

8.  Integrating buprenorphine treatment into office-based practice: a qualitative study.

Authors:  Declan T Barry; Kevin S Irwin; Emlyn S Jones; William C Becker; Jeanette M Tetrault; Lynn E Sullivan; Helena Hansen; Patrick G O'Connor; Richard S Schottenfeld; David A Fiellin
Journal:  J Gen Intern Med       Date:  2008-12-17       Impact factor: 5.128

9.  Validation of key behaviourally based mental health diagnoses in administrative data: suicide attempt, alcohol abuse, illicit drug abuse and tobacco use.

Authors:  Hyungjin Myra Kim; Eric G Smith; Claire M Stano; Dara Ganoczy; Kara Zivin; Heather Walters; Marcia Valenstein
Journal:  BMC Health Serv Res       Date:  2012-01-23       Impact factor: 2.655

Review 10.  Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review.

Authors:  Charlotte Kelly; Claire Hulme; Tracey Farragher; Graham Clarke
Journal:  BMJ Open       Date:  2016-11-24       Impact factor: 2.692

View more
  16 in total

1.  Financing Buprenorphine Treatment in Primary Care: A Microsimulation Model.

Authors:  Jonathan E Fried; Sanjay Basu; Russell S Phillips; Bruce E Landon
Journal:  Ann Fam Med       Date:  2020-11       Impact factor: 5.166

Review 2.  Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.

Authors:  Bertha K Madras; N Jia Ahmad; Jenny Wen; Joshua Sharfstein Sharfstein
Journal:  NAM Perspect       Date:  2020-04-27

3.  Comparing the feasibility of four web-based recruitment strategies to evaluate the treatment preferences of rural and urban adults who misuse non-prescribed opioids.

Authors:  Elizabeth C Saunders; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch
Journal:  Prev Med       Date:  2021-09-07       Impact factor: 4.018

4.  Posttraumatic stress disorder in individuals seeking treatment for opioid use disorder in Vermont.

Authors:  Kelly R Peck; Nathaniel Moxley-Kelly; Gary J Badger; Stacey C Sigmon
Journal:  Prev Med       Date:  2021-09-29       Impact factor: 4.018

5.  Opioid Use Disorder Among Hospitalized Older Adults: Prevalence, Characteristics, and Discharge Status.

Authors:  Andrew R Zullo; Patience Moyo; Eric Jutkowitz; Wenhan Zhang; Kali S Thomas
Journal:  J Am Med Dir Assoc       Date:  2020-02-18       Impact factor: 4.669

6.  The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance.

Authors:  Alex K Gertner; Jason S Rotter; Margaret E Holly; Christopher M Shea; Sherri L Green; Marisa Elena Domino
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

7.  "Health Is on the Back Burner:" Multilevel Barriers and Facilitators to Primary Care Among People Who Inject Drugs.

Authors:  Delia Motavalli; Jessica L Taylor; Ellen Childs; Pablo K Valente; Peter Salhaney; Jennifer Olson; Dea L Biancarelli; Alberto Edeza; Joel J Earlywine; Brandon D L Marshall; Mari-Lynn Drainoni; Matthew J Mimiaga; Katie B Biello; Angela R Bazzi
Journal:  J Gen Intern Med       Date:  2020-09-11       Impact factor: 5.128

Review 8.  Identification and Management of Opioid Use Disorder in Primary Care: an Update.

Authors:  Joseph H Donroe; Elenore P Bhatraju; Judith I Tsui; E Jennifer Edelman
Journal:  Curr Psychiatry Rep       Date:  2020-04-13       Impact factor: 5.285

9.  Use of Medications for Treatment of Opioid Use Disorder Among US Medicaid Enrollees in 11 States, 2014-2018.

Authors:  Julie M Donohue; Marian P Jarlenski; Joo Yeon Kim; Lu Tang; Katherine Ahrens; Lindsay Allen; Anna Austin; Andrew J Barnes; Marguerite Burns; Chung-Chou H Chang; Sarah Clark; Evan Cole; Dushka Crane; Peter Cunningham; David Idala; Stefanie Junker; Paul Lanier; Rachel Mauk; Mary Joan McDuffie; Shamis Mohamoud; Nathan Pauly; Logan Sheets; Jeffery Talbert; Kara Zivin; Adam J Gordon; Susan Kennedy
Journal:  JAMA       Date:  2021-07-13       Impact factor: 56.272

10.  Development of an unannounced standardized patient protocol to evaluate opioid use disorder treatment in pregnancy for American Indian and rural communities.

Authors:  A Taylor Kelley; Marcela C Smid; Jacob D Baylis; Elizabeth Charron; Amy E Binns-Calvey; Shayla Archer; Saul J Weiner; Lori Jo Begaye; Gerald Cochran
Journal:  Addict Sci Clin Pract       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.